Skip to main content
SpringerLink
Log in
Book cover

Systems Biology in Biotech & Pharma

A Changing Paradigm

  • Book
  • © 2012

Overview

Authors:
  1. Aleš Prokop

    1. , Chemical and Biological Engineering, Vanderbilt University, Nashville, USA

    View author publications

    You can also search for this author in PubMed   Google Scholar

  2. Seth Michelson

    1. Genomic Health Inc, Redwood, USA

    View author publications

    You can also search for this author in PubMed   Google Scholar

  • Numerous step-by-step tutorials help the reader to learn quickly
  • Outline of key technologies and tools needed for the development of Systems Biology
  • Computational Systems Biology in Health and Disease
  • The use of Systems Biology for identifying drug targets
  • Includes supplementary material: sn.pub/extras

Part of the book series: SpringerBriefs in Pharmaceutical Science & Drug Development (BRIEFSPSDD)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

  1. Front Matter

    Pages i-xviii
    Download chapter PDF

  2. Introduction: Discovery and Development—New Facet of Industry, New Tools and Lead Optimization

    • Aleš Prokop, Seth Michelson
    Pages 1-10

  3. Discovery: Use of Systems Biology for Identifying Targets

    • Aleš Prokop, Seth Michelson
    Pages 11-23

  4. Integrative Systems Biology I—Biochemistry: Phase I Lead Discovery and Molecular Interactions

    • Aleš Prokop, Seth Michelson
    Pages 25-38

  5. Integrative Systems Biology II—Molecular Biology: Phase 2 Lead Discovery and In Silico Screening

    • Aleš Prokop, Seth Michelson
    Pages 39-49

  6. Discovery: Computational Systems Biology (CSB) in Health and Disease I

    • Aleš Prokop, Seth Michelson
    Pages 51-67

  7. Development: In Vivo Pharmacology—Systems Biology in Health and Disease II

    • Aleš Prokop, Seth Michelson
    Pages 69-76

  8. Development: Pharmacokinetics—Systems Biology in Health and Disease III

    • Aleš Prokop, Seth Michelson
    Pages 77-85

  9. Development: Multiscale CSB—Simulation Tools

    • Aleš Prokop, Seth Michelson
    Pages 87-102

  10. Development: Drug Formulation and Delivery

    • Aleš Prokop, Seth Michelson
    Pages 103-107

  11. Development: Preclinical Model Based Drug Development

    • Aleš Prokop, Seth Michelson
    Pages 109-113

  12. Systems Biology: Impact on Pharma and Biotech

    • Aleš Prokop, Seth Michelson
    Pages 115-127
Back to top

Keywords

About this book

The US is currently well ahead of the rest of the world in the development and application of SB and its principles especially as they pertain to basic medical research and development. This lead is largely due to its earlier start in the academic arena. However, there is evidence of rapid development in both the UK/EU and Japan, and the gap is narrowing, particularly in the UK. From an industrial point of view, the Pharmaceutical Industry based in the US and UK can capitalize on these opportunities and gain the benefits of this technology. Many educational institutions (particularly their medical divisions) at present are heavily business-oriented, realize that in this particular industrial environment, that every dollar counts.

Authors and Affiliations

  • , Chemical and Biological Engineering, Vanderbilt University, Nashville, USA

    Aleš Prokop

  • Genomic Health Inc, Redwood, USA

    Seth Michelson

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation